

November 1, 2005

Dainippon Sumitomo Pharma and Sumitomo Chemical Company file lawsuit against Pfizer

Dainippon Sumitomo Pharma, Co. Ltd
Sumitomo Chemical Company, Ltd

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Sumitomo Chemical Company, Ltd. ("Sumitomo Chemical") jointly filed a lawsuit on November 1, 2005 against Pfizer (Pfizer Limited and Pfizer Corp. collectively) in the Tokyo District Court, seeking a declaratory judgment that Pfizer has no justifiable ground upon which it may seek an injunction against the manufacture and sale of Amlodin (Generic name: Amlodipine Besilate) by DSP. The lawsuit also calls for a declaratory judgment that the respective status of Sumitomo Chemical and DSP as a licensee and a sublicensee under the License Agreement regarding the Pfizer's Amlodin technology remains valid notwithstanding the consummation of the statutory merger to form DSP.

As DSP and Sumitomo Chemical respectively announced on October 17 and October 21, Pfizer had filed a petition in the Tokyo District Court for a preliminary injunction demanding cessation of manufacture and sale of Amlodin by DSP, etc. DSP and Sumitomo Chemical firmly believe that they have duly hold their respective status under the License Agreement pursuant to the provisions thereof, and both companies have decided that they should have the legitimacy of their position affirmed by the Court.

DSP and Sumitomo Chemical both are confident that their claims will be fully upheld in this lawsuit.